Search clinical trials for: Salmeterol

Total 383 results

GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Bronchial Asthma

Japan
GlaxoSmithKline

Completed

WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes

Asthma
GlaxoSmithKline

Completed

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Sunovion

Completed

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
Sunovion

Completed

To Evaluate the Long-term Safety of (R,R)-Formoterol in Subjects With COPD

Chronic Obstructive Pulmonary Disease | Emphysema | Chronic Bronchitis

United States
University of California, San Diego
National Heart, Lung, and Blood Institute (NHLBI)

Completed

A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial (SAPS)

Asthma

United States
Intech Biopharm Ltd.

Completed

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Taiwan
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)

Pulmonary Disease, Chronic Obstructive
Organon and Co

Completed

Study of Inhaled Glucocorticosteroids/Long-Acting Bronchodilator Drugs in Subjects With Asthma That Have Been Taking Inhaled Glucocorticosteroids (Study P04705AM1)

Asthma
Sanofi
Regeneron Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma

Asthma

United States
University of Florida
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose-Response of Salmeterol in Children

Asthma

United States
AstraZeneca

Completed

Symbicort Onset of Action 1

Asthma
Allergy and Asthma Center of El Paso
GlaxoSmithKline

Unknown

Onset of Action of Advair Hydrofluoroalkane (HFA) 115/21 in Comparison to Symbicort Pressurised Metered-Dose Inhalers (pMDI) 160/4.5 Measured by Impulse Oscillometry (IOS)

Asthma

United States
GlaxoSmithKline

Completed

A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise

Bronchospasm | Activity/Exercise Induced Bronchospasm

United States
GlaxoSmithKline

Completed

Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids

Asthma

Russian Federation, Belgium, Poland, Spain, Denmark, Italy, Sweden, Netherlands, France, Lithuania, Latvia, Norway
Milton S. Hershey Medical Center
National Heart, Lung, and Blood Institute (NHLBI); Asthma Clinical Research...

Completed

Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)

Asthma

United States
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Romania, Ukraine, United States, Chile, Greece, Peru
GlaxoSmithKline

Completed

Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

Asthma
GlaxoSmithKline

Terminated

Study Of RV-39 In Patients Who Also Have Asthma

Asthma

United States
GlaxoSmithKline

Completed

Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Estonia, Denmark, Spain, Finland, Slovakia, United Kingdom, Italy, Lithuania
Intech Biopharm Ltd.

Completed

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Taiwan
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

Asthma

Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Russian Federation, Slovakia, South Africa, Spain, Turkey, United Kingdom
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma (AERO-PD)

Asthma

Greece
Columbia University

Completed

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes (ARGARG)

Asthma

United States
Respirent Pharmaceuticals Co Ltd.

Completed

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma

Asthma

Greece
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

Asthma

United States, Georgia, Hungary, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort (FLASH)

COPD

India, South Africa, Egypt, Australia, Israel, Lebanon, Turkey, Philippines, Malaysia, Taiwan, Saudi Arabia
Novartis Pharmaceuticals

Completed

Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD (COMBINE)

Chronic Obstructive Pulmonary Disease

Argentina, Dominican Republic, Panama, Mexico, Brazil, Chile, Ecuador, Honduras
GlaxoSmithKline

Completed

SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults

Asthma
Almirall, S.A.

Completed

A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid

Asthma

Germany, United Kingdom
University of Milan

Completed

Effect of Salmeterol on Fluid Clearance From Alveolar-Capillary Membrane in COPD Patients (SALM1)

Chronic Obstructive Pulmonary Disease | Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients | Bronchodilator Agents | Salmeterol

Italy
Fudan University
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Unknown

The Efficacy and Safety of Salmeterol/Fluticasone Propionate vs Atropium/Albuterol in Patients COPD

Chronic Obstructive Pulmonary Disease (COPD)

China
GlaxoSmithKline

Completed

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Canada, Germany, Spain, United States, Italy, Netherlands, South Africa, Sweden, France, Mexico, Australia
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Russian Federation, Spain, Netherlands, Hungary, Denmark, Poland, Czechia
University of Pennsylvania

Completed

Pilot Study of Tolcapone in Smokers

Nicotine Dependence

United States
GlaxoSmithKline

Completed

Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

Asthma

United States, Canada, Russian Federation, Mexico, Australia, Ukraine
GlaxoSmithKline

Completed

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Asthma
Boehringer Ingelheim

Completed

Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa
Sunovion

Completed

A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States
GlaxoSmithKline

Completed

Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications

Asthma

Netherlands
Leiden University Medical Center
GlaxoSmithKline; Academisch Ziekenhuis Groningen; Netherlands Organisation for... and other collaborators

Terminated

Modification Of Disease Outcome In COPD

Chronic Obstructive Pulmonary Disease

Netherlands
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment

COPD

Turkey
Washington University School of Medicine
Kamuzu University of Health Sciences

Withdrawn

Effectiveness of Oral Albendazole in the Treatment of Severe Acute Malnutrition

Kwashiorkor | Marasmus

Malawi
Novartis Pharmaceuticals

Completed

Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma

Asthma

Germany, Belgium, India, Romania, South Africa, Croatia, Estonia, Russian Federation, Netherlands, Israel, Thailand, Lebanon, Canada, Philippines, Poland, Slovakia, United Kingdom, China, Latvia, Italy, Argentina, Greece, Mexico, Austria and more
GlaxoSmithKline

Completed

A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))

Pulmonary Disease, Chronic Obstructive

France, Germany, Spain, Russian Federation, Belgium, Ukraine, Philippines, Italy, Poland
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
GlaxoSmithKline

Completed

Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Russian Federation, Sweden, United Kingdom
Novartis Pharmaceuticals

Completed

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Asthma

Germany, Netherlands, United Kingdom, China, Romania, Bulgaria

3

Subscribe